ADAR1 Capital Management, LLC and Daniel Schneeberger filed a Form 4 with the SEC on November 13, 2026, disclosing a purchase of 12,333 shares of NextCure, Inc. common stock on November 11, 2026.

Key Highlights

  • Purchase date: November 11, 2026, with 12,333 shares of NextCure, Inc. common stock acquired.
  • Weighted average price: $5.0999 per share, with individual transaction prices ranging from $5.0750 to $5.1000, inclusive.
  • Post-transaction ownership: 750,289 shares of common stock beneficially owned indirectly following the reported transaction.
  • Reporting persons: ADAR1 Capital Management, LLC and Daniel Schneeberger, identified as 10% owners of NextCure, Inc.
  • Indirect ownership: The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC.
  • Disclaimer: Each reporting person disclaims beneficial ownership of the securities except to the extent of their pecuniary interest, as stated in the filing.

ADAR1 Capital Management Discloses Open-Market Purchase in NextCure

According to the filing, ADAR1 Capital Management, LLC and Daniel Schneeberger, its sole manager, jointly reported the acquisition of 12,333 shares of NextCure, Inc. (NASDAQ:NXTC) common stock on November 11, 2026. The transaction code listed is "P," indicating an open-market purchase. The reported weighted average price was $5.0999 per share, with individual purchases executed at prices ranging from $5.0750 to $5.1000, inclusive. The filing notes that full details on the number of shares purchased at each separate price are available upon request to NextCure, Inc., any security holder, or the SEC staff.

The filing identifies both ADAR1 Capital Management, LLC and Daniel Schneeberger as 10% owners of NextCure, Inc. According to the filing, the securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and are deemed to be indirectly beneficially owned by both ADAR1 Capital Management, LLC and by Schneeberger as the entity's sole manager. Following the reported transaction, the total amount of NextCure common stock indirectly beneficially owned by the reporting persons is listed as 750,289 shares.

The filing includes a standard disclaimer stating that each reporting person "disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any," and specifies that the report "shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise." No derivative securities transactions were reported in Table II of the filing.

What Was Disclosed

ADAR1 Capital Management, LLC and Daniel Schneeberger disclosed an open-market purchase of 12,333 NextCure, Inc. common shares on November 11, 2026, at a weighted average price of $5.0999, bringing their indirectly held position to 750,289 shares.